Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.975p 0.95p 1.00p 0.975p 0.975p 0.975p 2,074,638.00 07:30:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.2 -0.0 - 25.79

Sareum (SAR) Latest News

More Sareum News
Sareum Takeover Rumours

Sareum (SAR) Share Charts

1 Year Sareum Chart

1 Year Sareum Chart

1 Month Sareum Chart

1 Month Sareum Chart

Intraday Sareum Chart

Intraday Sareum Chart

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
27/2/201721:42Sareum 2015 1,839.00
16/2/201710:07Sareum 2016716.00
12/12/201612:19SAR Sareum Drug Discovery Co.15,853.00
26/4/201617:292012 Sareum Unleashed4,546.00
20/4/201608:23SAR news is on its way. fasten your seatbelts!172.00

Add a New Thread

Sareum (SAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:32:310.9714,690142.49O
09:02:350.9724,541238.05O
08:50:430.95146,0001,387.00O
08:49:000.95235,2942,237.65O
08:42:170.96524,5535,010.01O
View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

DateSubject
28/2/2017
08:20
Sareum Daily Update: Sareum Holdings is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 0.98p.
Sareum Holdings has a 4 week average price of 1.05p and a 12 week average price of 0.91p.
The 1 year high share price is 1.65p while the 1 year low share price is currently 0.30p.
There are currently 2,645,223,988 shares in issue and the average daily traded volume is 17,122,179 shares. The market capitalisation of Sareum Holdings is £25,790,933.88.
13/1/2017
12:18
qs99: Just noticed Hyrbidian broker note out this morning....states that they expect completion of pre-clinical work on Aurora+FLT3, and progress on lead optimisation for TYK2. On a risked basis, I like this bit "we still see the shares as significantly undervalued with the potential to double and on an un-risked basis see the potential to unlock value up to a share price of circa 4.5p, should its programmes progress up the development curve" DYOR etc....
09/12/2016
15:01
goose feathers: Ho ho ho What have we here a brokers report Nope Name the brokers CASH BONANZA DIRECTORS at sareum Have no clinical trial on aurora ,cos they haven't been speaking to China too often they don't know what us happening And they have 2 even 3 years lead optimisation in usa but nothing to report What next a bonus for being international Share price to collapse after useless agm when nothing will be added No shareholder value ,just directors feeding frenzy. Sucking all the cash out of the company.
08/12/2016
19:33
norma_stitts: Maybe the SAR price is falling as the board members are selling up and moving their money in to brewery stocks? Supply and demand drives prices and judging by 'Goose Feathers' there is a strong demand for anything with ABV printed on the bottle...
08/12/2016
18:51
goose feathers: Ho ho ho what have we here. Yes February 12. Arthritis on tyk2 section .no core? Just read it and weep ,oh so typical of scientific Mitchell. Terrific result on arthritis but where is lupus, nope no mention....cos no grant. Oh ho ho what have we here 2013 research update, once again lead optimisation is .......well lead optimisation was mentioned as progressing . but where oh where is it. No . These directors cannot be trusted. Share price is to fall further .
06/12/2016
20:04
goose feathers: Why are there no independent directors. The company can afford it? So why not? Who owns the patents to Chk1. Not sareum,and not sareum shareholders Aurora,patents shareholders or Mr reader the man ,no director who went on proactive and failed to tell the truth and nothing but the truth, just how did they manage to avoid a question about Aurora overdue clinical trial- because it was a pathetic pr interview. And reader did not want the question asked cos he knew the answer which was price sensitive ,. Tyk2 ,where is the lead optimisation promised,another porky ,never mind the " institutions sniffing around". Where are these rampers coming from,all delighted by a share that has a share graph which tells the whole story. Indepent directors, not here cos I'd want to know about the statements made by scientific big piece of pie Mitchell, about deals. And the statements that were not made in the last 12 months. The share price will fall further ,no news is good news,no Not with the scientific Tim and read me my patents reader,and once again no one will trust them.share price has further to fall.
06/12/2016
18:32
goose feathers: The dons,and Andy's come lately and people who sold all ,now claim to be "here" for six years , well no you haven't.you sold remember you pressed the little sell button, They present a bust company pay cut when the sacked their workforce, had a wonderful director leave, and sold income earning unit.as a positive . Then this whinger at whingers says that no other pay rise or bonus until now. Well they didn't deserve a bonus , the company took finance from shareholders on the strength of statements about ten out of ten, they ramped the living daylights out of annual report about a deal year after year.they made statements concerning the first deal will be early the next ,well where is it .SRI wasn't a financial success,Hbei is no success, The share price has further to fall to come to terms with The DCF of the deal. A deal done by CRT/CPF ,not the sareum directors with extra large slices of pie. The directors are not the only ones economical with the truth,as the andy come lately types now are in full swing - the salary increases and bonus are revolting in view of the fact that they the directors did not tell the whole truth about aurora , and have delivered nothing from their own research pipeline.
01/12/2016
19:18
goose feathers: Price sensitive information. Aurora failure is price sensitive so why was it not given out earlier than the results. The share price really tells a story from great ( slightly undervalued and not the greatest company to do a deal with) first deal for chk 1 - to the usual Sareum everything is next year next august next summer next next next. The whole company with exception of chk1 is " run on the smell of an oily rag"
28/7/2016
07:11
h2owater: LSE bb:Today 07:49 Price: 0.70Arbitrage 882 postsmy interpretation of today's RNS:based on the below info contained within today's RNS is, that Sareum now has not one, but two known CHK1 inhibitors i.e. CT244747 which, in conjunction with radiotherapy, has the proven ability to effectively target and treat both head and neck cancers i.e. as disclosed by the ICR in 2013. In addition to the above extremely positive info, we also now have the second of our CHK1 compounds i.e. the CHK1 inhibitor CCT245737 which, as we have been informed, has just commenced first-in-human clinical trials targeting multiple cancer cures and as such and quite understandably is, currently subject to confidentiality in the context of information data release.In conclusion and in light of my above interpretation of the info as presented by Sareum, I am personally extremely upbeat with regard to where on the critical pathway of its myriad of compound developments, Sareum is currently positioned.http://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/movement-in-share-price/201607280700104505F/Observation No OpinionReply to postReport post
10/3/2016
13:42
duxy786: Share price movement Sareum, the specialist cancer drug discovery and development business, notes the recent movement in its share price and the Board would like to advise the market that, having published its interim results for the period ended 31 December 2015 on 24 February 2016, it is not aware of any undisclosed reason for this rise -------- Someone's gotta know something for the sustained rise last 3 days. What do you reckon LM, BS to keep the share price to a level by the BOD?
10/3/2016
12:57
duxy786: 10/03/2016 12:55pm UK Regulatory (RNS & others) Sareum (LSE:SAR) Intraday Stock Chart Today : Thursday 10 March 2016 Click Here for more Sareum Charts. TIDMSAR RNS Number : 7178R Sareum Holdings PLC 10 March 2016 SAREUM HOLDINGS PLC ("Sareum") Share price movement Sareum, the specialist cancer drug discovery and development business, notes the recent movement in its share price and the Board would like to advise the market that, having published its interim results for the period ended 31 December 2015 on 24 February 2016, it is not aware of any undisclosed reason for this rise. Sareum Holdings plc
Sareum share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170228 09:55:34